Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.’s Ario Pharma Raises $3M Series A For Cough Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.

Advertisement

Related Content

U.K Drug-Repurposing Program Expands, Attracts Industry Support
Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
Xention Siphons Off OAB Therapy Into New Spin Out, Provesica

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel